07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

Adempas riociguat: Final Phase IIIb data

Final data from 61 PAH patients who had an insufficient response to treatment with phosphodiesterase-5 (PDE-5) inhibitors alone or in combination with an endothelin receptor antagonist in the open-label, international Phase IIIb RESPITE trial showed...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

Adempas riociguat regulatory update

EMA’s CHMP recommended against the use of Adempas riociguat from Bayer to treat pulmonary hypertension associated with idiopathic interstitial pneumonia (PH-IIP). CHMP said the recommendation follows the early termination of the Phase II RISE-IIP trial...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big...
07:00 , May 23, 2016 |  BC Week In Review  |  Clinical News

Adempas riociguat: Phase IIb discontinued

Bayer discontinued the double-blind, placebo-controlled, international Phase IIb RISE-IIP trial in 147 patients after the study’s IDMC observed that patients receiving Adempas were at a “possible increased risk for death and other serious adverse events”...
00:37 , May 13, 2016 |  BC Extra  |  Clinical News

Bayer halts Adempas trial on safety concerns

Bayer AG (Xetra:BAYN) said it stopped the 147-patient Phase IIb RISE-IIP study of Adempas riociguat to treat pulmonary hypertension associated with idiopathic interstitial pneumonia (PH-IIP) after the study's independent DMC "observed that patients receiving riociguat...
08:00 , Feb 25, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Soluble guanylate cyclase (sGC)

Renal disease INDICATION: Diabetic nephropathy Rat studies suggest activating sGC could help treat diabetic nephropathy. In a rat model of diabetic nephropathy, oral 0.3, 1, 3 and 10 mg/kg doses of an undisclosed sGC activator...
07:00 , Jul 27, 2015 |  BioCentury  |  Product Development

Ironwood's local notion

Ironwood Pharmaceuticals Inc. is exploring how tissue-specific distribution can give its products additional activity or different clinical profiles suitable for new indications. The company reported Phase I data last week for IW-1973 , a stimulator...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Clinical News

Adempas riociguat regulatory update

Bayer said Japan approved a regulatory application to expand the label of Adempas riociguat to include treatment of pulmonary hypertension (PAH). The oral soluble guanylate cyclase (sGC) stimulator is approved in Japan to treat chronic...
08:00 , Jan 12, 2015 |  BioCentury  |  Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Company News

Bayer pharmaceuticals, other news

Bayer said it will focus on its life science businesses and spin out its material sciences division, Bayer MaterialScience, into a separate publicly listed company in the next 12-18 months. The pharma said the major...